Contentious Issues in Gout Management: The Story so Far

Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019, USACorrespondence: Naomi SchlesingerDepartment of Medicin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Talaat M, Park K, Schlesinger N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	gout treatment controversies Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/915a56298e6a4ac88198231cd92d9bb9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:915a56298e6a4ac88198231cd92d9bb9
record_format	dspace
spelling	oai:doaj.org-article:915a56298e6a4ac88198231cd92d9bb92021-12-02T17:04:44ZContentious Issues in Gout Management: The Story so Far1179-156Xhttps://doaj.org/article/915a56298e6a4ac88198231cd92d9bb92021-05-01T00:00:00Zhttps://www.dovepress.com/contentious-issues-in-gout-management-the-story-so-far-peer-reviewed-fulltext-article-OARRRhttps://doaj.org/toc/1179-156XMohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019, USACorrespondence: Naomi SchlesingerDepartment of Medicine, Division of Rheumatology, Rutgers Robert Wood Johnson Medical School, Medical Education Building, Room 468, New Brunswick, NJ, 08903-0019, USAEmail schlesna@rutgers.eduAbstract: Gout is the most common inflammatory arthritis worldwide. Although gout has been known for antiquity, many challenges still exist in gout management. It is vital to view gout as a chronic disease and not just treat the acute flare. There is a perception of gout as an acute disease requiring treatment only for acute flares. However, to combat the disease, chronic urate-lowering therapy, reducing the serum urate levels to below the saturation threshold of 6.8 mg/dL, and chronic anti-inflammatory prophylaxis, especially during urate-lowering therapy initiation, are needed. In this manuscript, we discuss some of the contentious issues in gout management. These include the timing of urate-lowering therapy initiation, which urate-lowering therapy to chose, should comorbidities influence our treatment, using genetic determinants, and patient perspectives to drive treatment and differences between gout treatment the American College of Physicians and Rheumatology guidelines for gout management: driving care.Keywords: gout, treatment, controversiesTalaat MPark KSchlesinger NDove Medical PressarticlegouttreatmentcontroversiesDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 111-122 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	gout treatment controversies Diseases of the musculoskeletal system RC925-935
spellingShingle	gout treatment controversies Diseases of the musculoskeletal system RC925-935 Talaat M Park K Schlesinger N Contentious Issues in Gout Management: The Story so Far
description	Mohamed Talaat,1 Kyle Park,1 Naomi Schlesinger2 1Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 2Division of Rheumatology, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 08903-0019, USACorrespondence: Naomi SchlesingerDepartment of Medicine, Division of Rheumatology, Rutgers Robert Wood Johnson Medical School, Medical Education Building, Room 468, New Brunswick, NJ, 08903-0019, USAEmail schlesna@rutgers.eduAbstract: Gout is the most common inflammatory arthritis worldwide. Although gout has been known for antiquity, many challenges still exist in gout management. It is vital to view gout as a chronic disease and not just treat the acute flare. There is a perception of gout as an acute disease requiring treatment only for acute flares. However, to combat the disease, chronic urate-lowering therapy, reducing the serum urate levels to below the saturation threshold of 6.8 mg/dL, and chronic anti-inflammatory prophylaxis, especially during urate-lowering therapy initiation, are needed. In this manuscript, we discuss some of the contentious issues in gout management. These include the timing of urate-lowering therapy initiation, which urate-lowering therapy to chose, should comorbidities influence our treatment, using genetic determinants, and patient perspectives to drive treatment and differences between gout treatment the American College of Physicians and Rheumatology guidelines for gout management: driving care.Keywords: gout, treatment, controversies
format	article
author	Talaat M Park K Schlesinger N
author_facet	Talaat M Park K Schlesinger N
author_sort	Talaat M
title	Contentious Issues in Gout Management: The Story so Far
title_short	Contentious Issues in Gout Management: The Story so Far
title_full	Contentious Issues in Gout Management: The Story so Far
title_fullStr	Contentious Issues in Gout Management: The Story so Far
title_full_unstemmed	Contentious Issues in Gout Management: The Story so Far
title_sort	contentious issues in gout management: the story so far
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/915a56298e6a4ac88198231cd92d9bb9
work_keys_str_mv	AT talaatm contentiousissuesingoutmanagementthestorysofar AT parkk contentiousissuesingoutmanagementthestorysofar AT schlesingern contentiousissuesingoutmanagementthestorysofar
_version_	1718381861470732288

Contentious Issues in Gout Management: The Story so Far

Ejemplares similares